Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2020

05.06.2020 | Research Article

Tigecycline-associated hypofibrinogenemia in a real-world setting

verfasst von: David Campany-Herrero, Maria Larrosa-Garcia, Pilar Lalueza-Broto, Lucas Rivera-Sánchez, Juan Espinosa-Pereiro, Jaume Mestre-Torres, Carles Pigrau-Serrallach

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background Tigecycline is a broad-spectrum antibiotic used to treat infections that do not respond to first-line treatments. High-doses and extended treatments are common; therefore, adverse events might be more frequent and severe than those observed in clinical trials. Several case-reports have referred hypofibrinogenemia in patients who received tigecycline. Objective To analyse the impact of tigecycline use on coagulation parameters, and identify which variables could be related with this. Setting The study was performed at Hospital Universitari Vall Hebron, in Barcelona, Spain. Method Observational, retrospective study. All patients older than 18, who received tigecycline for > 72 h from January 2016 to March 2018 were included. Clinical and laboratory data from before, during and at the end of tigecycline treatment were retrospectively collected. Differences between means were analyzed using the paired-sample Student’s t-test. Binary logistic regression was performed to identify risk factors for hypofibrinogenemia. Main outcome measure Mean difference in fibrinogen plasma concentration and INR, before and at the end of tigecycline treatment. Results 78 patients (mean age 65; SD ± 15.5 years) were identified. The most common indications for tigecycline treatment were abdominal (66%), respiratory tract (16%) and skin&soft tissue (10%) infections. High-dose tigecycline was used in 62% of cases and the median duration of treatment was 12 days. Hypofibrinogenemia occurred in 12 patients, 5 bleeding events were observed and 4 of them required fibrinogen administration. Tigecycline caused significant alterations in fibrinogen plasma concentration (mean decrease 1.76 g/L; IC 95% 1.36 to 2.15) as well as INR (mean increase 0.11; IC 95% 0.05 to 0.17). Both were recovered after treatment cessation. We identified duration of treatment > 4 weeks (OR = 6.6), high-dose tigecycline (OR = 4.75) and high protein C levels (OR = 4.2) as independent variables associated with fibrinogen decrease, but not renal impairment. Conclusions Tigecycline administration has been related with hypofibrinogenemia, especially when high-doses of tigecycline are used. Health professionals should be aware of the potentially severe tigecycline-associated hypofibrinogenemia and monitor coagulation during treatment, especially when high-doses of tigecycline are used.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis–authors' responses. J Antimicrob Chemother. 2011;66(12):2895–6.CrossRef Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis–authors' responses. J Antimicrob Chemother. 2011;66(12):2895–6.CrossRef
4.
Zurück zum Zitat Falagas M, Vardakas K, Tsiveriotis K, Triarides N, Tansarli G. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1–7.CrossRef Falagas M, Vardakas K, Tsiveriotis K, Triarides N, Tansarli G. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44(1):1–7.CrossRef
6.
Zurück zum Zitat Shen F, Han Q, Xie D, Fang M, Zeng H, Deng Y. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015;30:67–73.CrossRef Shen F, Han Q, Xie D, Fang M, Zeng H, Deng Y. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015;30:67–73.CrossRef
7.
Zurück zum Zitat Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89(10):1063–4.CrossRef Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89(10):1063–4.CrossRef
8.
Zurück zum Zitat Wu X, Zhao P, Dong L, Zhang X. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine. 2017;96(49):e9124.CrossRef Wu X, Zhao P, Dong L, Zhang X. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Medicine. 2017;96(49):e9124.CrossRef
9.
Zurück zum Zitat Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Varileiou S. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis. 2015;47(10):743–6.CrossRef Sabanis N, Paschou E, Gavriilaki E, Kalaitzoglou A, Varileiou S. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis. 2015;47(10):743–6.CrossRef
10.
Zurück zum Zitat Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2014;59(3):1650–5.CrossRef Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2014;59(3):1650–5.CrossRef
11.
Zurück zum Zitat Routsi C, Kokkoris S, Douka E, Ekonomidou F, Karaiskos I, Giamarellou H. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015;45(1):90–3.CrossRef Routsi C, Kokkoris S, Douka E, Ekonomidou F, Karaiskos I, Giamarellou H. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents. 2015;45(1):90–3.CrossRef
12.
Zurück zum Zitat Conde-Estévez D, Grau S, Horcajada J, Luque S. Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes. Int J Antimicrob Agents. 2010;36(5):471–2.CrossRef Conde-Estévez D, Grau S, Horcajada J, Luque S. Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes. Int J Antimicrob Agents. 2010;36(5):471–2.CrossRef
13.
Zurück zum Zitat De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90.CrossRef De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90.CrossRef
14.
Zurück zum Zitat Postier R, Green S, Klein S, Ellis-Grosse E, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther. 2004;26(5):704–14.CrossRef Postier R, Green S, Klein S, Ellis-Grosse E, Loh E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther. 2004;26(5):704–14.CrossRef
15.
Zurück zum Zitat Ellis-Grosse E, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infecti Dis. 2005;41(s5):S341–S353353.CrossRef Ellis-Grosse E, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infecti Dis. 2005;41(s5):S341–S353353.CrossRef
16.
Zurück zum Zitat Oliva M, Rekha A, Yellin A, Pasternak J, Campos M, Rose G, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infec Dis. 3074A;5(1):88.CrossRef Oliva M, Rekha A, Yellin A, Pasternak J, Campos M, Rose G, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infec Dis. 3074A;5(1):88.CrossRef
17.
Zurück zum Zitat Rhodes A, Evans L, Alhazzani W, Levy M, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552.CrossRef Rhodes A, Evans L, Alhazzani W, Levy M, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552.CrossRef
19.
Zurück zum Zitat Hemostasia y trombosis. In: Provan D, Baglin T, Dokal I, de Vos J. Manual de Hematología Clínica. Barcelona: 2017. pp 453–543. eBook ISBN: 9788491131816. Hemostasia y trombosis. In: Provan D, Baglin T, Dokal I, de Vos J. Manual de Hematología Clínica. Barcelona: 2017. pp 453–543. eBook ISBN: 9788491131816.
20.
Zurück zum Zitat Wu P, Wu C. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56–7.CrossRef Wu P, Wu C. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56–7.CrossRef
21.
Zurück zum Zitat Vasse M, Paysant J, Soria J, Mirshahi S, Vannier J, Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol. 1996;93(4):955–61.CrossRef Vasse M, Paysant J, Soria J, Mirshahi S, Vannier J, Soria C. Down-regulation of fibrinogen biosynthesis by IL-4, IL-10 and IL-13. Br J Haematol. 1996;93(4):955–61.CrossRef
22.
Zurück zum Zitat Fuller G. The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers. J Cell Biol. 1985;101(4):1481–6.CrossRef Fuller G. The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers. J Cell Biol. 1985;101(4):1481–6.CrossRef
Metadaten
Titel
Tigecycline-associated hypofibrinogenemia in a real-world setting
verfasst von
David Campany-Herrero
Maria Larrosa-Garcia
Pilar Lalueza-Broto
Lucas Rivera-Sánchez
Juan Espinosa-Pereiro
Jaume Mestre-Torres
Carles Pigrau-Serrallach
Publikationsdatum
05.06.2020
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2020
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01072-7

Weitere Artikel der Ausgabe 4/2020

International Journal of Clinical Pharmacy 4/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.